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Abstract
Background/Aim: Viral eradication in chronic hepatitis C patients with sustained
virological response (SVR) after interferon (IFN) therapy remains controversial.
Methods: During a long-term follow-up study, 157 patients with SVR to IFN-a-2b-
based therapy were investigated with a transcription-mediated ampliﬁcation (TMA)
assay in serum. The hepatitis C virus (HCV) antibody was assessed by measuring the
optical density (OD) (Axsym HCV v3.0) and the semiquantitative titres (RIBA HCV
v3.0) of the HCV antibodies directed against the core, NS3, NS4 and NS5 proteins. A
control group included 23 untreated patients with persistently normal serum alanine
aminotransferase and detectable serum HCV-RNA. Results: The median duration of
follow-up was 4.0 (0–10) years. Serum HCV-RNA remained undetectable in all
patients. The mean HCV antibody OD were 93 19 and 45 21 before therapy and
in the last available serum sample respectively (P=0.001). There was a marked decrease
in the HCV antibodies directed against the NS3, NS4 and NS5 proteins (P=0.001),
while the core protein titre remained strongly positive. The 23 control patients were
followed for a median of 5 (2–14) years. The mean HCVantibody OD were 65 14 and
64 19 in the ﬁrst and the last measurements, respectively (NS), and HCV antibody
titres for structural and non-structural proteins remained unchanged. Conclusion: This
long-term study evaluating 157 patients demonstrated that SVR assessed by TMA is
durable, and HCVantibodies were markedly decreased (mainly those directed against
the non-structural proteins), emphasizing an absence of ongoing infection. These
results strongly suggest that HCV infection cured in patients who achieve an SVR.
The goal of antiviral therapy in patients with chronic hepatitis
C virus (HCV) infection is to attain a sustained virological
response (SVR), resulting in viral eradication in most patients
(1). In the past decade, antiviral therapy for chronic hepatitis C
has markedly improved with the addition of ribavirin and
pegylated interferon (PEG-IFN) (2, 3), resulting in a signiﬁcant
improvement in SVR rates. When patients achieve SVR there is
a very low risk of virological relapse (4, 5). Treatment-induced
viral eradication is associated with an improvement in liver
histological lesions. Several studies have reported an improve-
ment in liver ﬁbrosis in patients successfully treated with IFN-
based therapy (6–8).
Although the liver is the main site of viral replication, HCV
may also be found in extrahepatic locations such as peripheral
blood mononuclear cells (PBMC) (9). Persistent viral RNA in
the PBMC of patients who have either spontaneously cleared
serum HCV-RNA or have cleared it after anti-HCV therapy has
been reported (10–12). Conversely, two recent studies (8–13)
have reported the absence of detectable HCV-RNA in the
PBMC and/or the liver in patients with SVR achievement after
antiviral therapy.
However, although viral eradication is well documented in
patients with SVR, changes in antibodies to HCV status remain
unclear. The diagnosis of resolved hepatitis C infection is based
on the detection of the HCV-speciﬁc antibody and the absence
of detectable serum HCV-RNA. Complete or partial serocon-
version of the HCV antibody is characterized by a progressive
non-synchronized loss of these antibodies (14, 15). Several
studies have been performed to deﬁne the features of the
humoral immune response to HCV infection; only a few small
studies have focused on the dynamics of change in HCV-
speciﬁc antibodies in relation to treatment-induced viral eradi-
cation (16–18).
The aim of the present study was to investigate the dynamics
of change in various HCV antibodies in patients with chronic
hepatitis C who achieved SVR after antiviral therapy.
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Patients
A total of 1278 patients with histologically proven chronic
hepatitis C received IFN-a-2b-based therapy, from 1990 to
2006, in our outpatient clinic. Chronic hepatitis C was deﬁned
as the presence of the HCV antibody, detectable serum HCV-
RNA and elevated (twice the upper limit of normal) serum
alanine aminotransferase (ALT) levels. SVR was deﬁned as
normal ALTand undetectable serum HCV-RNA with transcrip-
tion-mediated ampliﬁcation (TMA), at the end of treatment and
after6 monthspost-treatment follow-up. Ina previous study (8),
344 patients with SVR were evaluated for residual HCV-RNA in
the liver and PBMC and liver histology improvement. In the
present study, a subgroup of 157 patients were evaluated for a
long-term follow-up of post-treatment HCVantibodies.
Inclusion criteria were SVR prospectively assessed in our
centre with TMA (available since January 2002) or an available
frozen serum sample for retrospective measurement with TMA
(before 2002). This study was approved by the University Ethics
Committee and performed in accordance with the principles of
the Declaration of Helsinki.
Control group
A control group of 23 untreated patients with persistently
normal serum ALT and ongoing infection (detectable serum
HCV-RNA) were studied for HCVantibody follow-up.
Follow-up
Serum HCV-RNA and serum ALT levels were measured every 6
months during the ﬁrst 3 years of follow-up and every other
year thereafter.
Hepatitis C virus RNA detection
Hepatitis C virus RNA was detected qualitatively with TMA
(VERSANT
TM HCV RNA Qualitative assay; Siemens Medical
Solution Diagnostics; sensitivity o9.6IU/ml, Eragny, France).
Hepatitis C virus antibody detection
Hepatitis C virus antibody measurement was performed with
the enzyme immunoassay HCV version 3.0 AXSYM (Abbott
Diagnostics Division, Wiesbaden, Germany) allowing detection
of the antibody against HCV core NS3 fusion protein and non-
structural proteins (c200, c100, NS5). Results were expressed as
optical density (OD) according to the manufacturer’s instruc-
tions. For each patient, the result is expressed in ratio (%); ‘OD
generated by the last available serum sample/OD generated at
baseline’. The ratio of decrease of HCV antibodies was deﬁned
as the difference between the baseline OD and the last measure-
ment OD divided by the baseline OD. Because the duration
between the two measurements was different, we calculated an
annual decrease by dividing the ratio by the interval of time
between the two measurements.
The amount and proﬁle of the HCVantibody was conﬁrmed
with the semiquantitative CHIRON-RIBA HCV 3.0 SIA assay
(Ortho clinical Diagnostics, Illkirch, France). This immunoblot
assay measures antibodies directed to both structural proteins
(core Ag, c22 synthetic peptide) and non-structural proteins
(NS3 Ag, c33c recombinant protein; NS4 Ag, mixed c5-1-1 and
c100 peptides; and NS5 Ag recombinant protein). The intensity
of the coloured bands is proportional to the amount of bound
antibody and is graded as 0 (none), 11 to 41, according to the
manufacturer’s instructions.
Statistical analysis
Quantitative variables were expressed as means standard
deviation (SD) or median with range. Statistical methods for
qualitative data included the w
2 test and the ANOVA test for
quantitative data. A two-sided P value of o0.05 was consid-
ered statistically significant.
Table 1. Baseline patients characteristics
Patients with SVR Control
Male, n (%) 118 (75) 5 (17)
Age (years)
Mean SD 46 11 45 10
Range 20–78 27–64
ALT (IU/ml)
Mean SD 113 75 26 8
Range 45–350 11–40
Anti-HCV OD
Mean SD 92 19 65 14
Range 28–125 43–106
Mode of infection (n,% )
Blood transfusion 36 (23) 6 (26)
Injection drug use 52 (33) 6 (26)
Unknown 69 (45) 11 (48)
HCV-RNA
Median (log10IU/ml) 5.537 5.215
Range 2.259–7.532 3.602–6.000
HCV genotype (n,% )
1 68 (43) 13 (56)
2 25 (16) 3 (13)
3 47 (30) 5 (22)
4–5 17 (11) 2 (9)
Fibrosis stage (n,% ) 
F0–F1 54 (37)
F2 55 (37) Not available
F3 24 (17)
F4 13 (9)
Pretreatment status (n,% )
Naı ¨ve 94 (60) –
Non-responders 26 (17) –
Relapsers 37 (23) –
Treatment regimens (n,% )
IFN-a-2bw 12 (8) –
IFN-a-2b plus RBVz 24 (15) –
PEG-IFN-a-2b plus RBV‰ 121 (77) –
Liver histology was graded according to the METAVIR scoring system:
F0, no ﬁbrosis; F1, portal ﬁbrosis without septa; F2, portal ﬁbrosis with
rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis.
wIntron A, at a dose of 3 million units three times a week for 6 months.
zIntron A in combination with ribavirin (Rebetol; Schering Plough
Research Institute, Kenilworth, NJ, USA), at a dose of 3 million units
three times a week in combination with ribavirin at a dose of
800–1200mg/day according to body weight.
‰PEG-Intron (Schering Plough Research Institute) at a dosage of 1.5mg/
kg body weight per week, and ribavirin (Rebetol; Schering Plough
Research Institute) at a dosage of 800–1200mg/day.
ALT, alanine aminotransferase; HCV, hepatitis C virus; IFN, interferon;
OD, optical density; RBV, ribavirin; SD, standard deviation; SVR, sustained
virological response.
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Patients
The baseline demographical, clinical, virological and histo-
logical characteristics of the 157 patients are shown in Table 1.
The mean duration of follow-upwas 4.6 2.1 years(median 4.0;
range 0–10 years). The patients contributing data are shown
in Table 2.
Clinical outcomes
Serum ALT levels remained normal in 147/157 (94%) patients.
In 10 patients (6%), serum ALT levels ﬂuctuated between
normal and twice the upper limit of normal (three patients
were overweight, one consumed excessive amounts of alcohol,
two had diabetes, one had active chronic hepatitis B, one had
steatosis and two had no cofactors). None of the 14 patients
Fig. 2. Changes in semiquantitative hepatitis C virus (HCV) antibody titres [recombinant immunoblot assay (RIBA)] measured before therapy
and at the end of a long-term follow-up in 157 patients successfully treated with interferon-based therapy.
aBaseline.
bYears. (A) HCVantibody
directed against NS4 protein (c100). (B) HCVantibody directed against core protein (c22). (C) HCVantibody directed against NS3 protein (c33).
(D) HCVantibody directed against NS5 protein (NS5). During the follow-up, 3, 10 and 26% of NS3, NS4 and NS5 bands became undetectable
respectively.
Fig. 1. Dynamics changes in hepatitis C virus (HCV) antibody in 157
patients during a long-term follow-up after sustained virological
response (SVR) to interferon-based therapy.
aExpressed as ratio (%)
optical density (OD) generated by the last available serum sample/
OD generated at baseline.
bBaseline.
cEnd of treatment.
Table 2. Patients contributing data at each time point during
follow-up
Follow-up EOT
0 1w 2w 3w 4w 5w 6w 7–9w Z10w
nz nz nz nz nz nz nz nz nz
Serum HCV-RNA
(n=278)
– 278 278 243 202 154 91 59 39 4
HCVantibody
(n=157)‰,z
66 14 7 12 27 35 23 9 28 2
Inclusion in the study (6 months after treatment cessation).
wYears after inclusion.
zNumber of patients tested at this time point.
‰Number of patients available for this data.
zSixty-six patients had an additional testing at the end of treatment.
EOT, end of treatment; HCV, hepatitis C virus.
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Maylin et al. SVR and clearance of HCV-RNAwith cirrhosis at baseline developed decompensated cirrhosis.
All 157 patients were alive at the end of follow-up.
Virological outcomes
Serum HCV-RNA remained undetectable in all the serum
samples tested during follow-up, indicating that none of the
patients relapsed.
Hepatitis C virus antibody measurement
Hepatitis C virus antibody measurements were performed in all
the patients when treatment began, and on the last available serum
sample during follow-up, 66 patients had an end-of-treatment
measurement. The mean OD was 92 19 and 45 2i nt h e
pretreatment and end-of-follow-up serum samples respectively
(P=0.0001). The dynamics of OD change according to the delay
between baseline and the last measurement is shown in Figure 1.
Therewas a signiﬁcant decreasein recombinant immunoblot
assay (RIBA)-HCV titres and proﬁles of antibodies directed
against the NS3, NS4 and NS5 proteins during the follow-up
(P=0.01), while antibodies directed against the core protein
remained strongly positive (41) in 87% of the patients
(Fig. 2A–D). There was no correlation between changes in
RIBA titres and patient characteristics (Table 3).
The median annual decrease was 11% from the initial ratio
(mean SD 10 12%; range 1–50%). In order to look for an
association between the magnitude of anti-HCV ratio decrease
and patients’baseline characteristics, the patients wereclassiﬁed
into low (  11%) decrease vs high (411%) decrease (Table 3)
with regard to the median annual anti-HCV ratio decrease. No
association was found between patient characteristics and low
vs high annual anti-HCV decrease.
The characteristics of the 23 untreated patients with persis-
tently normal ALTare shown in Table 1. The mean duration of
follow-up was 6.18 3.16 years (median 5.0; 4–13 years).
Serum HCV-RNA remained detectable in all patients during
follow-up. The mean OD was 65 14 and 64 19 in the ﬁrst
and the last measurements respectively (NS). RIBA titres and
proﬁles remained unchanged during follow-up (Fig. 3A–D),
contrary to patients with SVR.
Figure 4A and B shows the dynamics of OD and the RIBA-
HCV proﬁles for one patient with an SVR and one untreated
patient with persistently normal serum ALT.
Discussion
Patients with an SVR are frequently lost to follow-up soon after
therapy because these patients are considered cured and less apt
to come for a post-treatment check-up. Therefore, regular and
long-term follow-up of patients with SVR is not well documen-
ted, in particular, the dynamics of changes in the HCVantibody.
This study conﬁrms that there is no residual infection in serum
in patients with SVR. On the basis of RIBA-HCV, there was a
marked decrease in the antibodies directed to the non-structur-
al proteins (NS3, NS4 and NS5), while the antibodies against
the HCV core proteins (c22) remained strongly positive.
In the present study, none of the patients experienced a
relapse during the follow-up period. The discrepancies between
our results and other studies that report a relapse up to 5 years
after treatment cessation may be because of the use of a
less sensitive assay than TMA to assess the end-of-treatment
response and thus overestimation of SVR (8–19, 20). Indeed, in
our previous study (1), one out of 80 patients who achieved an
SVR (assessed with an in-house polymerase chain reaction
assay) developed a late relapse. An end-of-treatment serum
sample from this patient was retested with TMA and
demonstrated the presence of serum HCV-RNA (unpublished
data), indicating that this patient was in fact a non-responder.
Although there are reports on changes in the HCVantibody
or RIBA-HCV titres in patients who spontaneously resolve
HCV infection (21), or soon after the end of therapy (22),
there are very few reports on the long-term follow-up of the
dynamics of changes in the HCV antibody after successful
therapy (16–18). In our study, on the basis of RIBA, antibody
against core protein remained strongly positive in most
patients, whereas antibody against HCV non-structural
proteins showed a marked decrease. The observation of longer
persistence of core antibodies, in comparison with non-
structural antibodies, could indicate that this structural protein
involved in the constitution of the viral particle is synthesized in
excess. Indeed, the structural core protein is the most immuno-
genic HCV polypeptide, and antibodies appear earlier than
non-structural antibodies with a higher titre (23). A marked
Table 3. Characteristics of the patientsaccording to anti-hepatitis C
virus ratio annual decrease
Characteristic
  11% 411%
P n=77 n=80
Male, n (%) 46 (60%) 56 (70%) 0.858
Age (years)
Mean SD 48 11 45 10
Range (31–79) (20–78) 0.267
ALT level (IU/ml)
Mean SD 129 80 129 88
Range (40–372) (45–520) 0.648
Anti-HCV OD
Mean SD 95 21 92 16
Range (28–126) (39–123) 0.143
Mode of infection (n,% )
Blood transfusion 23 (31) 29 (36)
Injection drug use 26 (33) 24 (30) 0.750
Unknown 28 (36) 28 (34)
Serum HCV-RNA
Median (log10IU/ml) 5.525 5.477 0.102
Range (3.390–6.765) (2.259–7.532)
HCV genotype (n,% )
1 30 (43) 34 (43)
2 13 (18) 18 (23) 0.471
3 19 (28) 24 (30)
4–5 8 (11) 3 (3)
Fibrosis stage (n,% ) 
F0–F1 23 (36) 18 (28)
F2 24 (37) 24 (38) 0.173
F3 10 (15) 16 (25)
F4 8 (12) 6 (9)
Pretreatment status (n,% )
Naive 33 (43) 56 (57)
Non-responders 17 (22) 15 (19) 0.433
Relapsers 27 (34) 19 (24)
Liver histology was graded according to the METAVIR scoring system:
F0, no ﬁbrosis; F1, portal ﬁbrosis without septa; F2, portal ﬁbrosis with
rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis.
ALT, alanine aminotransferase; HCV, hepatitis C virus; OD, optical
density; SD, standard deviation.
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SVR and clearance of HCV-RNA Maylin et al.Fig. 3. Changes in semi-quantitative hepatitis C virus (HCV) antibody titres [recombinant immunoblot assay (RIBA)] measured in 23 untreated
patients with persistently normal alanine aminotransferase (ALT) and detectable HCV-RNA followed for a long-term period.
aBaseline.
bYears.
(A) HCVantibody directed against NS4 protein (c100). (B) HCVantibody directed against core protein (c22). (C) HCVantibody directed against
NS3 protein (c33). (D) HCVantibody directed against NS5 protein (NS5).
Fig. 4. Long-term follow-up of the dynamics of alanine aminotransferase (HCV) antibody optical density (OD) and recombinant immunoblot
assay (RIBA) proﬁles in one patient with sustained virological response (SVR) and one patient with persistently normal alanine aminotransferase
(ALT) and detectable HCV-RNA.
aBaseline.
bEnd of treatment. (A) Patients with SVR (resolved infection).(B) Patient with persistently normal ALT
and detectable serum HCV-RNA (ongoing infection).
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Maylin et al. SVR and clearance of HCV-RNAdecrease was found in the antibodies directed against the NS3,
NS4 and NS5 proteins, which have been reported to be
associated with viral replication (NS3, NS5) (23–25), or to be
highly immunogenic (NS4) (25), emphasizing the absence of
ongoing antigenic stimulation in our patients with SVR. These
results support the study by Nikolaeva et al. (23) showing that
the humoral immune response to non-structural HCV proteins
is short lived and might be a marker of infected cells. Adecrease
in the antibodies against the NS3, NS4 and NS5 proteins,
observed in our study, could reﬂect a decrease in infected cells,
suggesting that there is no antigenic stimulation after viral
eradication. Furthermore, NS3 and NS5 antibody titres have
been reported to be markers for chronicity (26) with a rapid
signiﬁcant decrease after treatment-induced viral eradication or
in immunocompetent patients with self-resolved infection.
This ﬁnding is supported by our previous study (27) showing
signiﬁcantly lower HCV antibody titres in untreated patients
with persistently normal ALT and without detectable serum
HCV-RNA (absence of ongoing infection) comparedwith those
with detectable serum HCV-RNA (ongoing infection). Further-
more, our data are supported by the study by Takaki et al. (14)
reporting a gradual decrease and disappearance in the HCV-
speciﬁc antibody after recovery from HCV infection. Evidently,
humoral immune response to non-structural proteins is short
lived and might be a marker of infected cells destruction.
Finally, the ﬁnding that HCV antibody titres of structural and
non-structural proteins remained unchanged in untreated
patients with persistently normal ALT and ongoing infection
(detectable serum HCV-RNA) also supports our results.
In conclusion, this study is durable, associated with an
absence of detectable serum HCV-RNA and a marked
decrease in HCV antibodies, especially those directed against
the non-structural NS3, NS4 and NS5 proteins. These results
strongly suggest that HCV infection is cured in patients who
achieve an SVR.
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